CORDIS
EU research results

CORDIS

English EN
IBD: proteases offer new targets for drug discovery

IBD: proteases offer new targets for drug discovery

Objective

The inflammatory bowel diseases (IBD) which comprise Crohn’s disease and ulcerative colitis are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract. The frequency of these conditions has increased in recent decades, particularly in countries making the transition from developing to developed nation status. In western Europe, IBD now affects between 1/1000 and 5/1000 of the population, and the prevalence of the conditions in new EU accession countries appears to be growing as they develop. Few conditions in all of clinical medicine are linked with as much morbidity and potential mortality as IBD. Current treatment is based upon steroid therapy or neutralizing the effect of pro-inflammatory cytokines, especially TNFalpha. Despite their efficacy, many patients eventually require surgery for refractory disease or complications (stricture, perforation, abscess). In response to the call we have assembled a multidisciplinary team of international experts to delineate the role of intestinal proteases and their inhibitors in the pathophysiology of IBD. A particularly innovative aspect of our approach is the examination of both bacterial and host derived proteases and interactions between the two. The ultimate aim is develop novel therapeutics and increased understanding of the disease both of which will impact within the wider EU community and globally.

Coordinator

THE UNIVERSITY OF SHEFFIELD

Address

Firth Court Western Bank
S10 2tn Sheffield

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 378 582

Administrative Contact

Joanne Watson (Ms.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 386 376

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 250 188

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA

Italy

EU Contribution

€ 148 200

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 594 800

MIKROBIOLOGICKY USTAV - AVCR, V.V.I.

Czechia

EU Contribution

€ 93 000

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 358 605

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

Ireland

EU Contribution

€ 112 200

ALIMENTARY HEALTH LTD

Ireland

EU Contribution

€ 195 000

THE UNIVERSITY OF AUCKLAND

New Zealand

EU Contribution

€ 107 463

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 374 836

Project information

Grant agreement ID: 202020

Status

Closed project

  • Start date

    1 June 2008

  • End date

    31 May 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 878 507,20

  • EU contribution

    € 2 999 250

Coordinated by:

THE UNIVERSITY OF SHEFFIELD

United Kingdom